These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

527 related items for PubMed ID: 9732070

  • 1. Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patients.
    Vidal C, García F, Gatell JM, Leal M, Clotet B, Pumarola T, Miró JM, Mallolas J, Ruiz L, Cruceta A, Tortajada C.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Sep 01; 19(1):55-60. PubMed ID: 9732070
    [Abstract] [Full Text] [Related]

  • 2. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
    AIDS; 1998 Oct 01; 12(14):F151-60. PubMed ID: 9792371
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
    Albrecht MA, Hughes MD, Liou SH, Katzenstein DA, Murphy R, Balfour HH, Para MF, Valdez H, Hammer SM, ACTG 303 Study Team.
    AIDS Res Hum Retroviruses; 2000 Sep 20; 16(14):1337-44. PubMed ID: 11018853
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Genotypic resistance to zidovudine as a predictor of failure of subsequent therapy with human immunodeficiency virus type-1 nucleoside reverse-transcriptase inhibitors.
    Venturi G, Romano L, Catucci M, Riccio ML, De Milito A, Gonnelli A, Rubino M, Valensin PE, Zazzi M.
    Eur J Clin Microbiol Infect Dis; 1999 Apr 20; 18(4):274-82. PubMed ID: 10385016
    [Abstract] [Full Text] [Related]

  • 7. Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial.
    Bussmann H, Wester CW, Thomas A, Novitsky V, Okezie R, Muzenda T, Gaolathe T, Ndwapi N, Mawoko N, Widenfelt E, Moyo S, Musonda R, Mine M, Makhema J, Moffat H, Essex M, Degruttola V, Marlink RG.
    J Acquir Immune Defic Syndr; 2009 May 01; 51(1):37-46. PubMed ID: 19282782
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators.
    Kuritzkes DR, Marschner I, Johnson VA, Bassett R, Eron JJ, Fischl MA, Murphy RL, Fife K, Maenza J, Rosandich ME, Bell D, Wood K, Sommadossi JP, Pettinelli C.
    AIDS; 1999 Apr 16; 13(6):685-94. PubMed ID: 10397563
    [Abstract] [Full Text] [Related]

  • 10. Evidence for prolonged clinical benefit from initial combination antiretroviral therapy: Delta extended follow-up.
    Delta Coordinating Committee.
    HIV Med; 2001 Jul 16; 2(3):181-8. PubMed ID: 11737399
    [Abstract] [Full Text] [Related]

  • 11. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
    Paris D, Ledergerber B, Weber R, Jost J, Flepp M, Opravil M, Ruef C, Zimmerli S.
    AIDS Res Hum Retroviruses; 1999 Dec 10; 15(18):1631-8. PubMed ID: 10606086
    [Abstract] [Full Text] [Related]

  • 12. Dual nucleoside regimens in nonadvanced HIV infection: prospective follow-up of 130 patients, Aquitaine Cohort, 1996 to 1998. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA).
    Morlat P, Marimoutou C, Dequae-Merchadou L, Pellegrin I, Mercié P, Neau D, Beylot J, Dabis F.
    J Acquir Immune Defic Syndr; 2000 Mar 01; 23(3):255-60. PubMed ID: 10839661
    [Abstract] [Full Text] [Related]

  • 13. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Katlama C, Ingrand D, Loveday C, Clumeck N, Mallolas J, Staszewski S, Johnson M, Hill AM, Pearce G, McDade H.
    JAMA; 1996 Jul 10; 276(2):118-25. PubMed ID: 8656503
    [Abstract] [Full Text] [Related]

  • 14. A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients.
    Ungsedhapand C, Kroon ED, Suwanagool S, Ruxrungtham K, Yimsuan N, Sonjai A, Ubolyam S, Buranapraditkun S, Tiengrim S, Pakker N, Kunanusont C, Lange JM, Cooper DA, Phanuphak P.
    J Acquir Immune Defic Syndr; 2001 Jun 01; 27(2):116-23. PubMed ID: 11404532
    [Abstract] [Full Text] [Related]

  • 15. Baseline HIV type 1 genotypic resistance to a newly added nucleoside analog is predictive of virologic failure of the new therapy.
    Van Vaerenbergh K, Van Laethem K, Van Wijngaerden E, Schmit JC, Schneider F, Ruiz L, Clotet B, Verhofstede C, Van Wanzeele F, Muyldermans G, Simons P, Stuyver L, Hermans P, Evans C, De Clercq E, Desmyter J, Vandamme AM.
    AIDS Res Hum Retroviruses; 2000 Apr 10; 16(6):529-37. PubMed ID: 10777143
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. Delta Coordinating Committee and Virology Group.
    AIDS; 1999 Apr 01; 13(5):565-73. PubMed ID: 10203381
    [Abstract] [Full Text] [Related]

  • 18. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
    Izopet J, Bicart-See A, Pasquier C, Sandres K, Bonnet E, Marchou B, Puel J, Massip P.
    J Med Virol; 1999 Dec 01; 59(4):507-11. PubMed ID: 10534734
    [Abstract] [Full Text] [Related]

  • 19. Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study. Early Anti-Retroviral Therapy Study.
    García F, Alonso MM, Romeu J, Knobel H, Arrizabalaga J, Ferrer E, Dalmau D, Ruiz I, Vidal F, Frances A, Segura F, Gomez-Sirvent JL, Cruceta A, Clotet B, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM.
    J Acquir Immune Defic Syndr; 2000 Sep 01; 25(1):26-35. PubMed ID: 11064501
    [Abstract] [Full Text] [Related]

  • 20. Delavirdine: a review of its use in HIV infection.
    Scott LJ, Perry CM.
    Drugs; 2000 Dec 01; 60(6):1411-44. PubMed ID: 11152019
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.